Shares of CureVac N.V. (CVAC) plummeted 5.03% in Thursday's trading session following the release of the company's fourth quarter and full-year 2024 financial results. The German biopharmaceutical firm, focused on developing messenger RNA (mRNA) therapeutics and vaccines, reported mixed results that appear to have disappointed investors.

For the fourth quarter, CureVac posted a pre-tax loss of €38.6 million, an improvement from the €86.5 million loss in the same period last year. However, revenues declined to €14.5 million from €22.6 million in Q4 2023. The full-year results showed a significant revenue increase to €535.2 million, largely due to a one-time €400 million upfront payment from a new licensing agreement with GSK. Despite this, the company's operating expenses remained high, resulting in an operating profit of €177.7 million for the year.

While CureVac highlighted strategic milestones in its oncology pipeline and reported a cash position of €481.7 million at the end of 2024, investors seem concerned about the company's ongoing losses and the sustainability of its revenue growth. The market reaction suggests that shareholders may be looking for more concrete progress in CureVac's clinical programs and a clearer path to profitability. As the company continues to invest heavily in research and development, particularly in its mRNA-based cancer immunotherapies, the balance between advancing its pipeline and managing expenses will be crucial for future investor confidence.